Bogdan Zurawski

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: Th...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 november 2025

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-smal...

European journal of cancer (Oxford, England : 1990) · 9 september 2025

Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label,...

The Lancet. Oncology · 2025-07

Langetermijn overleving met nivolumab-ipilimumab als eerstelijns bij NSCLC: CheckMate 227/9LA langetermijn

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-01

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemoth...

European journal of cancer (Oxford, England : 1990) · 2024-11

Systemische en intracraniële uitkomsten met nivolumab-ipilimumab bij NSCLC-hersenmetastasen: CheckMate 227/9LA

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023-08

Niraparib plus abiraterone bij mCRPC: MAGNITUDE fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 juni 2023

Cabozantinib plus nivolumab-ipilimumab bij niercelcarcinoom: COSMIC-313 definitief

The New England journal of medicine · 11 mei 2023

Nivolumab-ipilimumab versus EXTREME bij recidief hoofd-halscarcinoom: CheckMate 651 fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 april 2023

Adjuvant nivolumab plus ipilimumab versus placebo na nefrectomie bij RCC: CheckMate 914 fase III

Lancet (London, England) · 11 maart 2023

Nivolumab plus ipilimumab als eerstelijns bij NSCLC: CheckMate 227 vierjaars

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022-02

Nivolumab plus ipilimumab versus chemotherapie bij PD-L1≥1% NSCLC: CheckMate 227 vierjaars

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021-04

Nivolumab plus cabozantinib versus sunitinib bij gevorderd RCC: CheckMate 9ER fase III

The New England journal of medicine · 4 maart 2021

Nivolumab plus ipilimumab plus twee cycli chemotherapie bij NSCLC: CheckMate 9LA fase III

The Lancet. Oncology · 2021-02

Nivolumab plus ipilimumab bij gevorderd NSCLC: CheckMate 227 Part 1 definitief

The New England journal of medicine · 21 november 2019